Unlikely as USA still a risk with more Countries to challenge Drug failures.
Drugs not selling with more problems to come as Sales start to Crash Hence No Update for 2025!!!!
On the Edge of Failure!! |
AZN is GSK's future |
Tempted to buy but need to wait until see what these buffoons say in Parliament at 12.30.If increase Divi tax not sure it would be worth risk in a share like this |
I'd give my shares for £17.50... Not too much of a premium..... |
It was up on the Zantac news. We are seeing a typical pile on on a UK stock that has few buyers like all of them. Few buyers because UK pension funds have walked away from our whole mkt due to 30 years of woeful governments |
They should buy e-therapeutics .. used to be listed on AIM but now private. Pocket change for GSK |
This is a dog of a company and a dog of a share. They should be motoring away post Zantac and instead the share price remains battered with every new RNS ..Someone take this s#*t show over please! |
This is all poor communications in my opinion. If GSK announced it was using AI for drug discovery, the price would be up 20%. |
If they were they'd be taken out |
Emma has done nothing wrong and these are a bargain |
Yep, can't hide behind zantac anymore |
Emma needs to go. Her time is up !!! |
Can 1400 hold? |
Market hates the Results down over 2% |
Added. Can't resist with such a stupid fall with the general mkt |
Maintained divi despite 1.8 billion payout for Zantac from existing resources. Medicines pipeline away from vaccines-for which GSK is now one of the leading big pharma producers worldwide-better than it has been for years. Good position for substantial future divi play. |
Great results |
GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases. |
TM - I, too, was thinking of the former. |
 "It would be interesting to read why they chose this site over other options."
Alphorn - could have been planned as a massive hedge to curry favour with the US authorities in case the Zantac litigation went wrong ....
Or a connection to:
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
This public-private agreement marks the first time that HHS has taken a “portfolio approach” to funding drug development with a private sector company. This unique collaboration provides flexibility to move funding around GSK’s antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens.
Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to a total of $200 million if the agreement is renewed over five years. |
Blame the Labour government. |
It would be interesting to read why they chose this site over other options. May well be fiscal deductions against the huge US income?
edit: a bit more - worth a read. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
